# NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)

Source: https://welltoldgrants.com/grants/rfa-hl-23-004-nhlbi-outstanding-investigator-award-oia-r35-clinical-trial/  
Official notice: https://www.grants.gov/search-results-detail/333353

> National Institutes of Health offered grants of up to $700,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 20 awards worth $20.0 million in total. Applications closed on April 25, 2024.

| Field | Value |
|---|---|
| Opportunity number | RFA-HL-23-004 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | April 25, 2024 |
| Award ceiling | $700,000 |
| Award floor | not stated |
| Expected awards | 20 |
| Total funding | $20.0 million |
| Cost sharing | not required |
| Assistance Listings | 93.233, 93.837, 93.838, 93.839, 93.840 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

## What the grant funds

The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. The OIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the OIA must be within the scope of the NHLBI mission (https://www.nhlbi.nih.gov/about/mission-statement). It is anticipated that the OIA will: Provide a stable funding environment, thereby improving productivity and facilitating nimble, ambitious, creative research; Accelerate scientific innovation by enabling flexibility in pursuing new research directions as they arise, since PD/PIs will not be bound to specific aims proposed in advance of the studies; Reduce the time researchers spend writing grant applications and managing multiple grant awards, thereby allowing more time to be devoted to conducting research; Facilitate PD/PIs commitment to research through increased stability of funding; and Enable PD/PIs to devote more time and energy to mentoring students and junior scientists and providing scientific service.

## Questions people ask

### Is RFA-HL-23-004 still open?

No. It closed on April 25, 2024. A newer notice is open: RFA-HL-26-002, closes April 28, 2027 (172 days left).

### Who can apply for NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)?

Closed April 25, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $700,000 each. About $20.0 million in total across about 20 awards.

### Who has been funded under RFA-HL-23-004?

NIH RePORTER lists 36 projects funded under RFA-HL-23-004 in fiscal 2023 to 2026, at 28 institutions. The most were at University of Michigan at Ann Arbor, Cincinnati Childrens Hosp Med Ctr, Columbia University Health Sciences.

### Who has won Cardiovascular Diseases Research grants before?

The largest recipients over five fiscal years were The Trustees of the University of Pennsylvania, Brigham & Womens Hospital Inc, Regents of the University of Michigan. The program made 11,798 awards worth $15 billion in that time.